A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.

Weijia CaiMai Q NguyenNicole A Wilski Timothy J Purwin Megane VernonManoela TiagoAndrew E Aplin

Published in: Cancer research (2022)

Targeting PDPK1 stimulates antitumor immunity and sensitizes NRAS mutant melanoma to MEK inhibition, providing rationale for the clinical development of a combinatorial approach for treating patients with melanoma.

Keyphrases

genome wide
wild type
skin cancer
dna methylation
pi k akt
clinical trial
basal cell carcinoma
high throughput
cancer therapy
signaling pathway
copy number
induced apoptosis
cell proliferation
oxidative stress